Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...7071727374757677787980...123124»
  • ||||||||||  lenvatinib / Generic mfg.
    Clinical, Journal:  Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. (Pubmed Central) -  Nov 17, 2021   
    The optimal cut-off value of the ALBI score for predicting survival was nearly the same as the value separating mALBI grades 2a and 2b. In conclusion, the mALBI grade was a better predictor of survival than the Child-Pugh classification in patients with unresectable HCC who received lenvatinib therapy.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. (Pubmed Central) -  Nov 17, 2021   
    The second-line systemic treatments available for hepatocellular carcinoma include regorafenib, cabozantinib, ramucirumab, and, more recently, immune checkpoint inhibitors...This setup elucidates the response to chronic inflammation and the altered balance between tolerance and immune response in HCC development. This paper provides an overview of the mechanisms involved in HCC pathogenesis, with a special focus on the immune implications, along with current and future clinical perspectives.
  • ||||||||||  temozolomide / Generic mfg., lenvatinib / Generic mfg.
    Multi-institution Retrospective Experience with Lenvatinib for Progressive Malignant Glioma (Exhibit Hall D) -  Nov 16, 2021 - Abstract #SNO2021SNO_391;    
    Clincal Benefit Rate (PR+SD) to Lenvatinib in recurrent disease was 57%, with 29% Partial Responses and 29% Stable Disease as best radiographic response. This retrospective cohort supports further evaluation of the efficacy of Lenvatinib in recurrent malignant glioma in a clinical trial.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases (Exhibit Hall D) -  Nov 16, 2021 - Abstract #SNO2021SNO_321;    
    Response to treatment will be determined using RANO-BM for intracranial disease and RECIST 1.1 for systemic disease. Study accrual is anticipated over 12-24 months with anticipated total study duration of 30 months.
  • ||||||||||  Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Safety and efficacy of lenvatinib as first-line systemic therapy for advanced hepatocellular carcinoma – a real-world single-centre retrospective analysis ([VIRTUAL]) -  Nov 16, 2021 - Abstract #NCRI2021NCRI_303;    
    Systemic therapies have expanded in recent years to include atezolizumab-bevacizumab, regorafenib, cabozantinib, lenvatinib and ramucirumab as well as sorafenib...Understanding potential predictive factors for lenvatinib in HCC remains critical and effects on quality-of-life need to be understood. Impact statement Our real-world data show inferior survival outcomes to those found in the REFLECT trial, although rates of radiologic response were similar, and it is important to understand the reasons for this to optimise therapeutic outcomes for advanced HCC patients treated outside of clinical trials.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Lenvatinib plus EGFR inhibition for liver cancer. (Pubmed Central) -  Nov 16, 2021   
    Additionally, lack of approved post-lenvatinib systemic therapies is a serious issue in the real world. No abstract available
  • ||||||||||  lenvatinib / Generic mfg.
    Clinical, PK/PD data, Journal:  Pharmacokinetic study of lenvatinib in Chinese patients with solid tumors. (Pubmed Central) -  Nov 10, 2021   
    P1
    Lenvatinib pharmacokinetic data in Chinese patients are consistent with data in multinational trials, supporting usage of the 24-mg dose. Clinical Trial Registration: NCT03009292 (ClinicalTrials.gov).
  • ||||||||||  Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
    Journal:  Lenvatinib: Established and Promising Drug for the Treatment of Advanced Hepatocellular Carcinoma. (Pubmed Central) -  Nov 6, 2021   
    Immune checkpoint inhibitors (ICIs) are now part of HCC treatment, and recently the combination of atezolizumab plus bevacizumab has become the recommended standard of care first-line therapy for selected patients. The antitumor and immunomodulatory activities that lenvatinib shows in preclinical studies, and the positive outcomes achieved using a combination of lenvatinib plus ICIs, open new perspectives for advanced HCC treatment.
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Journal:  Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab. (Pubmed Central) -  Nov 6, 2021   
    This case showed that even if atezolizumab plus bevacizumab is not effective, multidisciplinary treatment such as LEN and conversion surgery is possible. Given the efficacy of LEN after atezolizumab plus bevacizumab, it is important to consider that there is a possibility of cure even when first-line treatment is not effective for a patient with unresectable HCC.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal, Combination therapy, Checkpoint inhibition:  The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma. (Pubmed Central) -  Nov 4, 2021   
    Even with the successful launch of sorafenib for the clinical treatment of HCC in 2007, the long-term survival for patients with HCC is still suboptimal, largely due to the occurrence of primary or acquired drug resistance...While lenvatinib, cabozantinib, regorafenib, and the monoclonal antibody ramucirumab, as well as the immune checkpoint inhibitors (ICIs) atezolizumab, nivolumab, and pembrolizumab, have all shown promise in clinical trials, ICIs, especially when administered in combination with molecular-targeted drugs or cytotoxic drugs, have drawn increased attention...A more thorough knowledge of novel treatment strategies should help in decision making for advanced HCC therapy. The present review summarizes the mechanisms of HCC tumorigenesis, relevant trial results for approved HCC therapies, future perspectives, and major challenges for the overall treatment of HCC.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Journal:  Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. (Pubmed Central) -  Nov 1, 2021   
    Sorafenib may not be a candidate for use as a posttreatment agent after lenvatinib, according to the results of the present study. Regorafenib has the potential to become an appropriate posttreatment agent after lenvatinib.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Clinical, P3 data, Journal:  Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. (Pubmed Central) -  Nov 1, 2021   
    Among patients who received lenvatinib and experienced a treatment-related treatment-emergent adverse event leading to withdrawal, 6.6% had an ALBI grade of 1, while 13.3% had an ALBI grade of 2, and 7.9% had a CPS of 5, while 12.1% had a CPS of 6. Better liver function at baseline, as measured by ALBI grade or CPS, may be prognostic for better survival outcomes in patients with uHCC undergoing treatment with lenvatinib or sorafenib.